Landscape of Genetic Alterations in Patients with Acute Myeloid Leukemia and the Implications in Personalized Medicine

Abstract Genetic alterations play important roles in the pathogenesis of acute myeloid leukemia (AML). With advances in genomics, many gene mutations have been detected in AML, and some specific mutations are included in international classifications and risk stratification. Gene mutations can be targets for the development of novel agents and biomarkers for monitoring measurable/minimal residual disease (MRD). Personalized medicine according to the genetic risk at presentation and MRD after treatment can not only improve survival but also reduce toxicity from therapies. This review focuses on the landscape of gene mutations and their clinical implications in patients with AML.